Filtered By:
Specialty: Cardiology
Drug: Aspirin
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 932 results found since Jan 2013.
Lateral medullary syndrome: uncommon form of brainstem stroke
CONCLUSION: LMS is a rare form of brainstem stroke and carries a favorable prognosis if early hospitalization and treatment is applied. Brain MRI, including diffusion sequence, is the most useful diagnostic tool for detecting LMS.PMID:36923779 | PMC:PMC10010825 | DOI:10.1097/MS9.0000000000000260
Source: Atherosclerosis - March 16, 2023 Category: Cardiology Authors: Abdiwahid Ahmed Ibrahim Ahmet Bakir Nor Osman Sidow Abdiladhif Mohamed Ali Mohamed Farah Osman Abdulkadir Ahmed Mohamed Sheikh Hassan Source Type: research
Young Patients Undergoing Carotid Endarterectomy Have Increased Rates of Recurrent Disease and Late Neurologic Events
CONCLUSIONS: Young patients undergoing CEA are more likely to be African American, female, and active smokers. They are more likely to present symptomatically and undergo non-elective CEA. Although perioperative outcomes are similar, younger patients are more likely to experience carotid occlusion or restenosis as well as subsequent neurological events, during relatively short follow-up. These data suggest that younger CEA patients may require more diligent follow-up, and a continued aggressive approach to medical management of atherosclerosis to prevent future events related to the operated artery, given the particularly ...
Source: Atherosclerosis - March 4, 2023 Category: Cardiology Authors: Molly Ratner Karan Garg Heepeel Chang William Johnson Mikel Sadek Thomas Maldonado Neal Cayne Jeffrey Siracuse Glenn Jacobowitz Caron Rockman Source Type: research
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
ConclusionsConsidering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2.5 mg twice daily should be considered the preferred regimen for S-ASCVD patients with low bleeding risk.
Source: American Journal of Cardiovascular Drugs - March 3, 2023 Category: Cardiology Source Type: research
Tirofiban Superior to Aspirin in Stroke Without Large Occlusion Tirofiban Superior to Aspirin in Stroke Without Large Occlusion
Among patients with disabling strokes without medium or large occlusions, more of those taking tirofiban had good function at 90 days than those on aspirin, results of the RESCUE BT2 trial show.Medscape Medical News
Source: Medscape Cardiology Headlines - March 2, 2023 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease
Eur J Med Res. 2023 Feb 23;28(1):93. doi: 10.1186/s40001-023-01050-5.ABSTRACTIschemic cerebrovascular disease (ICVD) is a major cause of mortality and disability worldwide and is often caused by atherosclerosis. As a systemic disease, atherosclerosis usually affects multiple vascular beds, mainly including cerebral, coronary, and peripheral arteries. Therefore, ICVD is easily complicated by lower-extremity peripheral arterial disease (PAD). ICVD patients with PAD have more serious symptoms and a worse prognosis, however, neurologists might neglect the evaluation and management of the coexistent PAD, and there is still a la...
Source: Atherosclerosis - February 24, 2023 Category: Cardiology Authors: Lu-Guang Li Xin Ma Source Type: research
Early DAPT Improves Outcomes for Strokes With No Other Tx Options
(MedPage Today) -- DALLAS -- Adding tirofiban (Aggrastat) to aspirin for dual antiplatelet therapy (DAPT) within 24 hours of acute ischemic stroke improved outcomes for patients who weren't candidates for thrombolytic or endovascular treatment...
Source: MedPage Today Cardiovascular - February 12, 2023 Category: Cardiology Source Type: news
Monitoring antiplatelet therapy: where are we now?
J Cardiovasc Med (Hagerstown). 2022 Dec 15. doi: 10.2459/JCM.0000000000001406. Online ahead of print.ABSTRACTSingle antiplatelet therapy represents the cornerstone of thrombosis prevention in atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y12 inhibitor, is the standard of care for patients with acute coronary syndrome or undergoing both coronary and peripheral percutaneous interventions. Recent data suggest the efficacy of DAPT also after minor stroke. In this setting, a large body of evidence has documented that genetic and acquired patients' characteristics may af...
Source: Atherosclerosis - February 2, 2023 Category: Cardiology Authors: Rossella Marcucci Martina Berteotti Felice Gragnano Mattia Galli Ilaria Cavallari Giulia Renda Piera Capranzano Francesca Santilli Davide Capodanno Dominick J Angiolillo Plinio Cirillo Paolo Calabr ò Giuseppe Patti Raffaele De Caterina Working Group of T Source Type: research
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
Conclusions. In REWIND, most women met clinically relevant treatment targets, but in lower proportions than men. Women had a lower risk for all cardiovascular outcomes except stroke. Clinical trials.gov registration number: NCT01394952.PMID:36723445 | DOI:10.1080/14017431.2023.2166101
Source: Scandinavian Cardiovascular Journal - February 1, 2023 Category: Cardiology Authors: Giulia Ferrannini Juan M Maldonado Sohini Raha Purnima Rao-Melacini Rutaba Khatun Charles Atisso Linda Shurzinske Hertzel C Gerstein Lars Ryd én M Angelyn Bethel Source Type: research
Rationale and design of a randomised double-blind 2 ×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
CONCLUSION: The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.TRIAL REGISTRATION NUMBER: NCT03635749.PMID:36707080 | DOI:10.1136/svn-2022-002084
Source: Atherosclerosis - January 27, 2023 Category: Cardiology Authors: Ying Gao Yuesong Pan Shangrong Han Weiqi Chen Jing Jing Chunjuan Wang Yingying Yang Tingting Wang Xia Meng Xingquan Zhao Liping Liu Hao Li S Claiborne Johnston Pierre Amarenco Philip M Bath Yongjun Wang Yilong Wang INSPIRES Investigators Source Type: research
Prognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
Conclusions: Small dense LDL-cholesterol level was a significant risk factor for cardiovascular events following presentations of acute coronary syndrome.PMID:36676782 | DOI:10.3390/medicina59010158
Source: Atherosclerosis - January 21, 2023 Category: Cardiology Authors: Teruhiko Imamura Masakazu Hori Nikhil Narang Hiroshi Ueno Koichiro Kinugawa Source Type: research
Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial ...
Source: Atherosclerosis - January 10, 2023 Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research
